This database contains 337 studies, archived under the term: "neuropsychological tests"
Click here to filter this large number of results.
Longitudinal changes of fractional anisotropy in Alzheimer’s disease patients treated with galantamine: a 12-month randomized, placebo-controlled, double-blinded study
Likitjaroen, Y.,
Meindl, T.,
Friese, U.,
Wagner, M.,
Buerger, K.,
Hampel, H.,
Teipel, S. J.
Diffusion tensor imaging (DTI) demonstrates decline of fractional anisotropy (FA) as a marker of fiber tract integrity in Alzheimer’s disease (AD). We aimed to assess the longitudinal course of white matter microstructural changes in AD and healthy elderly control (HC) subjects and to evaluate the effects of treatment with the cholinesterase inhibitor galantamine on white […]
Two galantamine titration regimens in patients switched from donepezil
Engedal, K.,
Davis, B.,
Richarz, U.,
Han, J.,
Schäuble, B.,
Andreasen, N.
Objectives: In addition to inhibiting acetylcholinesterase, galantamine has allosteric-modulating activity at nicotinic receptors. This may make galantamine an attractive option for patients starting treatment for Alzheimer’s disease (AD), but also for those who have not benefited from their current therapy. This study explored outcomes in subjects with AD transitioning from donepezil because of insufficient tolerability […]
Medication adherence and tolerability of Alzheimer’s disease medications: study protocol for a randomized controlled trial
Campbell, Noll L.,
Dexter, Paul,
Perkins, Anthony J.,
Gao, Sujuan,
Li, Lang,
Skaar, Todd C.,
Frame, Amie,
Hendrie, Hugh C.,
Callahan, Chris M.,
Boustani, Malaz A.
Background: The class of acetylcholinesterase inhibitors (ChEI), including donepezil, rivastigmine, and galantamine, have similar efficacy profiles in patients with mild to moderate Alzheimer’s disease (AD). However, few studies have evaluated adherence to these agents. We sought to prospectively capture the rates and reasons for nonadherence to ChEI and determine factors influencing tolerability and adherence.; Methods/design: […]
Magnetic resonance imaging and neuropsychological results from a trial of memantine in Alzheimer’s disease
Weiner, Michael W.,
Sadowsky, Carl,
Saxton, Judith,
Hofbauer, Robert K.,
Graham, Stephen M.,
Yu, Sung Yun,
Li, Shaoyi,
Hsu, Hai-An,
Suhy, Joyce,
Fridman, Moshe,
Perhach, James L.
Background: This study was designed to assess changes in brain volume and cognitive abilities in memantine-treated patients with Alzheimer’s disease (AD) by using an exploratory, single-arm, delayed-start design.; Methods: Cholinesterase inhibitor-treated patients with AD (N = 47; Mini-Mental State Examination score range: 15-23) were enrolled in an observational lead-in period (weeks: 1-24), followed by an […]
Memantine and functional communication in Alzheimer’s disease: results of a 12-week, international, randomized clinical trial
Saxton, Judith,
Hofbauer, Robert K.,
Woodward, Michael,
Gilchrist, Nigel L.,
Potocnik, Felix,
Hsu, Hai-An,
Miller, Michael L.,
Pejović, Vojislav,
Graham, Stephen M.,
Perhach, James L.
Post hoc analyses suggest that memantine treatment may provide communication-related benefits in patients with Alzheimer’s disease (AD). In this 12-week, international, randomized, double-blind, placebo-controlled trial of memantine (10 mg bid), the functional communication abilities of patients with AD (MMSE range: 10-19) were assessed using the Functional Linguistic Communication Inventory (FLCI; primary measure). Two combined subscales […]
Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer’s disease
Salloway, Stephen,
Mintzer, Jacobo,
Cummings, Jeffrey L.,
Geldmacher, David,
Sun, Yijun,
Yardley, Jane,
Mackell, Joan
To better understand responses in the large number of US-based patients included in a global trial of donepezil 23 mg/d versus 10 mg/d for moderate-to-severe Alzheimer’s disease (AD), post hoc exploratory analyses were performed to assess the efficacy and safety in US and non-US (rest of the world [RoW]) patient subgroups. In both subgroups, donepezil […]
One-year repeated cycles of cognitive training (CT) for Alzheimer’s disease
Bergamaschi, Susanna,
Arcara, Giorgio,
Calza, Attilio,
Villani, Daniele,
Orgeta, Vasiliki,
Mondini, Sara
Background: Recent research suggests that a combination of both pharmacological and psychosocial treatments targeting cognitive functions improves cognition in patients with Alzheimer’s disease (AD). The present study evaluated the effectiveness of a 1-year cognitive training (CT) by comparing the cognitive performance of 16 patients with AD treated with CT and cholinesterase inhibitors (ChEIs) (experimental group) […]
Passive movement therapy in severe paratonia: a multicenter randomized clinical trial
Background: Paratonia causes severe movement dysfunction in late stage dementia. Passive Movement Therapy (PMT) is often used to decrease high muscle tone, but the efficacy has never been shown. The objective of this study is to investigate the effect of PMT on muscle tone after two and four weeks of treatment.; Methods: This study comprised […]
Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: a randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg
Herrschaft, Horst,
Nacu, Anatol,
Likhachev, Sergey,
Sholomov, Ilya,
Hoerr, Robert,
Schlaefke, Sandra
A multi-centre, double-blind, randomised, placebo-controlled, 24-week trial with 410 outpatients was conducted to demonstrate efficacy and safety of a 240 mg once-daily formulation of Ginkgo biloba extract EGb 761(®) in patients with mild to moderate dementia (Alzheimer’s disease or vascular dementia) associated with neuropsychiatric symptoms. Patients scored 9 to 23 on the SKT cognitive battery, […]